Notice
2025/10/23
OSAKA, Japan, Oct. 23, 2025 - Shionogi & Co., Ltd. (Head Office: Osaka, Japan; hereafter "Shionogi") is pleased to announce that an advertisement feature titled “Will nasal vaccines consign injections to history?”, highlighting our collaborative efforts with Chiba University on the development of innovative nasal vaccines, has been published in the print edition (October 23, 2025 issue) and online edition of the internationally renowned scientific journal Nature.
The advertisement feature can be found here: https://www.nature.com/articles/d42473-025-00238-z
This feature introduces the characteristics and potential of the nasal vaccines being jointly researched and developed by Shionogi and Chiba University. In particular, it highlights a novel approach that utilizes a delivery system designed to enhance the retention of vaccine antigens on the nasal mucosa. This technology aims not only to prevent the onset and severity of disease through systemic immunity, but also to induce local immunity at the site of pathogen entry, thereby providing an additional layer of protection.
Shionogi, in collaboration with Chiba University, is working to apply this technology to the development of next-generation vaccines. Through the creation and delivery of effective nasal vaccines, we aim to contribute to global health.
Forward-Looking Statements
This announcement contains forward-looking statements. These statements are based on expectations in light of the information currently available, assumptions that are subject to risks and uncertainties which could cause actual results to differ materially from these statements. Risks and uncertainties include general domestic and international economic conditions such as general industry and market conditions, and changes of interest rate and currency exchange rate. These risks and uncertainties particularly apply with respect to product-related forward-looking statements. Product risks and uncertainties include, but are not limited to, completion and discontinuation of clinical trials; obtaining regulatory approvals; claims and concerns about product safety and efficacy; technological advances; adverse outcome of important litigation; domestic and foreign healthcare reforms and changes of laws and regulations. Also for existing products, there are manufacturing and marketing risks, which include, but are not limited to, inability to build production capacity to meet demand, lack of availability of raw materials and entry of competitive products. The company disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise.
For Further Information, Contact:
SHIONOGI Website Inquiry Form: https://www.shionogi.com/global/en/contact.html